Membrane defence against complement lysis: The structure and biological properties of CD59
暂无分享,去创建一个
[1] Z. Fishelson. COMPLEMENT EVASION BY PARASITES: SEARCH FOR “ACHILLES' HEEL” , 1991, Clinical and experimental immunology.
[2] P. Sims,et al. Regulatory control of complement on blood platelets. Modulation of platelet procoagulant responses by a membrane inhibitor of the C5b-9 complex. , 1989, The Journal of biological chemistry.
[3] S. Maher,et al. Amplified gene expression in CD59-transfected Chinese hamster ovary cells confers protection against the membrane attack complex of human complement. , 1991, Journal of Biological Chemistry.
[4] T. Fujita,et al. A novel membrane glycoprotein capable of inhibiting membrane attack by homologous complement. , 1989, International immunology.
[5] D. Cooper. Is xenotransplantation a realistic clinical option? , 1992, Transplantation proceedings.
[6] V. Hořejší,et al. Large, detergent‐resistant complexes containing murine antigens Thy‐1 and Ly‐6 and protein tyrosine kinase p56lck , 1993, European journal of immunology.
[7] M. Medof,et al. Synthesis of aberrant decay-accelerating factor proteins by affected paroxysmal nocturnal hemoglobinuria leukocytes. , 1990, The Journal of clinical investigation.
[8] S. Matsuo,et al. Localization of 20‐kD homologous restriction factor (HRF20) in diseased human glomeruli. An immunofluorescence study , 1991, Clinical and experimental immunology.
[9] D. Fleenor,et al. Structure of the CD59-encoding gene: further evidence of a relationship to murine lymphocyte antigen Ly-6 protein. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[10] B. Morgan,et al. The sheep analogue of human CD59: purification and characterization of its complement inhibitory activity. , 1993, Immunology.
[11] M. Shin,et al. Cytolysis of nucleated cells by complement: cell death displays multi-hit characteristics. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[12] C. Parker,et al. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND GLYCOSYL PHOSPHATIDYLINOSITOL ANCHORED PROTEINS THAT REGULATE COMPLEMENT , 1991, Clinical and experimental immunology.
[13] H. Müller-Eberhard,et al. Inhibition of antibody-dependent lymphocyte cytotoxicity by homologous restriction factor incorporated into target cell membranes , 1987, The Journal of experimental medicine.
[14] R. Thompson,et al. REACTIVE LYSIS: THE COMPLEMENT-MEDIATED LYSIS OF UNSENSITIZED CELLS , 1970, The Journal of experimental medicine.
[15] J. Zajicek,et al. Oligodendrocytes lack glycolipid anchored proteins which protect them against complement lysis. Restoration of resistance to lysis by incorporation of CD59. , 1992, Immunology.
[16] D. Purcell,et al. Complement regulatory proteins at the feto‐maternal interface during human placental development: distribution of CD59 by comparison with membrane cofactor protein(CD46) and decay accelerating factor (CD55) , 1992, European journal of immunology.
[17] D. Fearon,et al. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. , 1982, Journal of immunology.
[18] M. Rosenfeld,et al. Synthesis of mannosylglucosaminylinositol phospholipids in normal but not paroxysmal nocturnal hemoglobinuria cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[19] T. Fujita,et al. Purification of 1F5 antigen that prevents complement attack on homologous cell membranes. , 1990, Journal of immunology.
[20] D. Neuhaus,et al. Sequence‐specific , 1993, Protein science : a publication of the Protein Society.
[21] H. Müller-Eberhard,et al. Deficiency of the homologous restriction factor in paroxysmal nocturnal hemoglobinuria , 1987, The Journal of experimental medicine.
[22] A. Weetman,et al. Antithyroid drugs and release of inflammatory mediators by complement-attacked thyroid cells , 1992, The Lancet.
[23] N. Motoyama,et al. Paroxysmal nocturnal hemoglobinuria due to hereditary nucleotide deletion in the HRF20 (CD59) gene , 1992, European journal of immunology.
[24] B. Morgan,et al. Isolation and characterization of the complement-inhibiting protein CD59 antigen from platelet membranes. , 1992, The Biochemical journal.
[25] W. Knapp,et al. GPI-anchored cell-surface molecules complexed to protein tyrosine kinases. , 1991, Science.
[26] E. Appella,et al. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. , 1990, The EMBO journal.
[27] H. Okada,et al. Structural properties of the glycoplasmanylinositol anchor phospholipid of the complement membrane attack complex inhibitor CD59 , 1992, Clinical and experimental immunology.
[28] Okada Hidechika,et al. Species-specific inhibition by gycophorin of complement activation via the alternative pathway , 1983 .
[29] J. Leddy,et al. Complement lysis of human erythrocytes. Differeing susceptibility of two types of paroxysmal nocturnal hemoglobinuria cells to C5b-9. , 1979, The Journal of clinical investigation.
[30] J. Sodetz,et al. Analysis of the specific association of the eighth and ninth components of human complement: identification of a direct role for the alpha subunit of C8. , 1985, Biochemistry.
[31] T. Fujita,et al. Monoclonal antibodies capable of causing hemolysis of neuraminidase-treated human erythrocytes by homologous complement. , 1989, Journal of immunology.
[32] T. Hideshima,et al. 20 KDa homologous restriction factor of complement resembles T cell activating protein. , 1989, Biochemical and biophysical research communications.
[33] N. Cooper. Complement evasion strategies of microorganisms. , 1991, Immunology today.
[34] T. Kinoshita,et al. Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria. , 1990, The New England journal of medicine.
[35] P. Sims,et al. The human complement regulatory protein CD59 binds to the alpha-chain of C8 and to the "b"domain of C9. , 1992, The Journal of biological chemistry.
[36] M. Nose,et al. Tissue distribution of HRF20, a novel factor preventing the membrane attack of homologous complement, and its predominant expression on endothelial cells in vivo. , 1990, Immunology.
[37] M. Tone,et al. Transfection of human CD59 complementary DNA into rat cells confers resistance to human complement , 1991, European journal of immunology.
[38] R. Schreiber,et al. Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[39] K. Hamilton,et al. Regulatory control of the terminal complement proteins at the surface of human endothelial cells: neutralization of a C5b-9 inhibitor by antibody to CD59. , 1990, Blood.
[40] W. Rosse. Paroxysmal nocturnal hemoglobinuria: the biochemical defects and the clinical syndrome. , 1989, Blood reviews.
[41] P. Sims,et al. Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9. , 1991, Journal of immunology.
[42] N. E. Hansen,et al. The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria. , 1992, Blood.
[43] J. Atkinson,et al. Physiologic relevance of the membrane attack complex inhibitory protein CD59 in human seminal plasma: CD59 is present on extracellular organelles (prostasomes), binds cell membranes, and inhibits complement- mediated lysis , 1993, The Journal of experimental medicine.
[44] C. Parker,et al. Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. , 1989, The Journal of clinical investigation.
[45] E. Reinherz,et al. A soluble multimeric recombinant CD2 protein identifies CD48 as a low affinity ligand for human CD2: divergence of CD2 ligands during the evolution of humans and mice , 1993, The Journal of experimental medicine.
[46] W. Rosse,et al. Relationship between the membrane inhibitor of reactive lysis and the erythrocyte phenotypes of paroxysmal nocturnal hemoglobinuria. , 1989, The Journal of clinical investigation.
[47] T. Hughes,et al. Isolation and characterization of a membrane protein from rat erythrocytes which inhibits lysis by the membrane attack complex of rat complement. , 1992, The Biochemical journal.
[48] E. Simpson,et al. A glycophospholipid anchor is required for Qa-2-mediated T cell activation , 1989, Nature.
[49] M. Kazatchkine,et al. Decreased Expression of the Membrane Inhibitor of Complement‐Mediated Cytolysis CD59 on T‐lymphocytes of HIV‐Infected Patients , 1992, AIDS.
[50] A. Bothwell,et al. Contribution of the N-linked carbohydrate of erythrocyte antigen CD59 to its complement-inhibitory activity. , 1992, The Journal of biological chemistry.
[51] S. Meri,et al. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. , 1990, Immunology.
[52] A. Weetman,et al. Expression and function of membrane attack complex inhibitory proteins on thyroid follicular cells. , 1992, Immunology.
[53] W. Hahn,et al. Overlapping but nonidentical binding sites on CD2 for CD58 and a second ligand CD59. , 1992, Science.
[54] J. Tschopp,et al. Absence of homologous restriction factor does not affect CTL‐mediated cytolysis , 1989, European journal of immunology.
[55] J. Takeda,et al. Deficient surface expression of glycosylphosphatidylinositol-anchored proteins in B cell lines established from patients with paroxysmal nocturnal hemoglobinuria. , 1992, International immunology.
[56] S. Meri,et al. Human protectin (CD59), an 18-20-kD homologous complement restriction factor, does not restrict perforin-mediated lysis , 1990, The Journal of experimental medicine.
[57] T. Takami,et al. A case of paroxysmal nocturnal hemoglobinuria without deficiency of decay-accelerating factor on erythrocytes. , 1990, Blood.
[58] N. Minato,et al. Isolation and expression of the full-length cDNA encoding CD59 antigen of human lymphocytes. , 1990, DNA and cell biology.
[59] E. Shevach,et al. CD59 functions as a signal-transducing molecule for human T cell activation. , 1991, Journal of immunology.
[60] P. Nicol,et al. Studies on the terminal stages of complement lysis. , 1973, Immunology.
[61] H. Okada,et al. Species‐specific restriction of complement by HRF20 (CD59) generated by cDNA transfection , 1992, European journal of immunology.
[62] I. Hanson,et al. The human BDNF gene maps between FSHB and HVBS1 at the boundary of 11p13-p14. , 1992, Genomics.
[63] N. Minato,et al. Cytoprotective effect of CD59 antigen on xenotransplantation immunity. , 1992, Transplantation Proceedings.
[64] E. Shevach,et al. Ly-6: a multigene family in search of a function. , 1989, Immunology today.
[65] P. Robinson,et al. Phosphatidylinositol membrane anchors and T-cell activation. , 1991, Immunology today.
[66] K. Austen,et al. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[67] M. Borowitz,et al. Defective glycosylphosphatidylinositol anchor synthesis in paroxysmal nocturnal hemoglobinuria granulocytes. , 1992, Blood.
[68] R. Schmidt,et al. Affected paroxysmal nocturnal hemoglobinuria T lymphocytes harbor a common defect in assembly of N-acetyl-D-glucosamine inositol phospholipid corresponding to that in class A Thy-1- murine lymphoma mutants. , 1992, The Journal of biological chemistry.
[69] K. Inoue,et al. The role of the C9b domain in the binding of C9 molecules to EAC1-8 defined by monoclonal antibodies to C9. , 1988, Journal of Immunology.
[70] A. Dalmasso,et al. REACTION OF COMPLEMENT WITH ENDOTHEUAL CELLS IN A MODEL OF XEN0TRANSPLANTATION , 1991, Clinical and experimental immunology.
[71] R. Taguchi,et al. Complete deficiency of 20 KDa homologous restriction factor (HRF20) and restoration with purified HRF20. , 1989, Biochemical and biophysical research communications.
[72] Y. Sugita,et al. Isolation from human erythrocytes of a new membrane protein which inhibits the formation of complement transmembrane channels. , 1988, Journal of biochemistry.
[73] I. Hilgert,et al. Characterization of a broadly expressed human leucocyte surface antigen MEM-43 anchored in membrane through phosphatidylinositol. , 1989, Molecular immunology.
[74] D. Roelcke,et al. Glycophorin A inhibits lysis by the complement attack phase. , 1983, Immunobiology.
[75] T. Yasuda,et al. Differing reactivities of human and guinea-pig complement on haptenized liposomes via the alternative pathway. , 1983, Molecular immunology.
[76] I. Rooney,et al. Membrane attack complex (MAC)-mediated damage to spermatozoa: protection of the cells by the presence on their membranes of MAC inhibitory proteins. , 1992, Immunology.
[77] H. Waldmann,et al. Gene structure of human CD59 and demonstration that discrete mRNAs are generated by alternative polyadenylation. , 1992, Journal of molecular biology.
[78] D. Lublin. Glycosyl-phosphatidylinositol anchoring of membrane proteins. , 1992, Current topics in microbiology and immunology.
[79] K. Yasukawa,et al. Molecular cloning and characterization of MACIF, an inhibitor of membrane channel formation of complement. , 1989, Journal of biochemistry.
[80] M. Lederman,et al. Heightened complement sensitivity of acquired immunodeficiency syndrome lymphocytes related to diminished expression of decay-accelerating factor. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[81] W. Philbrick,et al. The CD59 antigen is a structural homologue of murine Ly‐6 antigens but lacks interferon inducibility , 1990, European journal of immunology.
[82] T. Huizinga,et al. The Pi-linked receptor FcRIII is released on stimulation of neutrophils , 1988, Nature.
[83] D. Hourcade,et al. Expression of human decay accelerating factor or membrane cofactor protein genes on mouse cells inhibits lysis by human complement. , 1992, Transplantation proceedings.
[84] V. Hořejší,et al. Association of the CD59 and CD55 cell surface glycoproteins with other membrane molecules. , 1991, Journal of immunology.
[85] V. Hořejší,et al. The nature of large noncovalent complexes containing glycosyl-phosphatidylinositol-anchored membrane glycoproteins and protein tyrosine kinases. , 1992, Journal of immunology.
[86] A. Bernard,et al. A 19-kDa human erythrocyte molecule H19 is involved in rosettes, present on nucleated cells, and required for T cell activation. Comparison of the roles of H19 and LFA-3 molecules in T cell activation. , 1989, Journal of immunology.
[87] B. Fleckenstein,et al. Herpesvirus saimiri has a gene specifying a homologue of the cellular membrane glycoprotein CD59. , 1992, Virology.
[88] C. Browning,et al. On Chemical Combination and Toxic Action as Exemplified in Haemolytic Sera , 1904, Proceedings of the Royal Society of London.
[89] G. Klein,et al. Expression of the complement regulatory proteins CD21, CD55 and CD59 on Burkitt lymphoma lines: their role in sensitivity to human serum‐mediated lysis , 1992, European journal of immunology.
[90] M. Deckert,et al. CD59 molecule: A second ligand for CD2 in T cell adhesion , 1992, European journal of immunology.
[91] M. Daha,et al. CD59 expressed by human endothelial cells functions as a protective molecule against complement‐mediated lysis , 1992, European journal of immunology.
[92] J. Richardson,et al. The toxin-agglutinin fold. A new group of small protein structures organized around a four-disulfide core. , 1980, The Journal of biological chemistry.
[93] H. Müller-Eberhard,et al. Self-protection of cytotoxic lymphocytes: a soluble form of homologous restriction factor in cytoplasmic granules. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[94] V. Nussenzweig,et al. Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein , 1986, The Journal of experimental medicine.
[95] Michael Loran Dustin,et al. Deficiency of lymphocyte function-associated antigen 3 (LFA-3) in paroxysmal nocturnal hemoglobinuria. Functional correlates and evidence for a phosphatidylinositol membrane anchor , 1987, The Journal of experimental medicine.
[96] T. Hideshima,et al. HRF20, a membrane inhibitor of complement attack, does not protect cells from the cytotoxic reaction by lymphokine activated killer cells. , 1990, Biochemical and biophysical research communications.
[97] W. Roberts,et al. Structural basis for variations in the sensitivity of human decay accelerating factor to phosphatidylinositol-specific phospholipase C cleavage. , 1990, Journal of immunology.
[98] D L Simmons,et al. CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells , 1989, The Journal of experimental medicine.
[99] D. Fearon. ANTI‐INFLAMMATORY AND IMMUNOSUPPRESSIVE EFFECTS OF RECOMBINANT SOLUBLE COMPLEMENT RECEPTORS , 1991, Clinical and experimental immunology.
[100] J. Atkinson,et al. Evolution of the complement system. , 1991, Immunology today.
[101] D. Anstee,et al. New monoclonal antibodies in CD59: use for the analysis of peripheral blood cells from paroxysmal nocturnal haemoglobinuria (PNH) patients and for the quantitation of CD59 on normal and decay accelerating factor (DAF)-deficient erythrocytes. , 1992, Immunology.
[102] P. Sims,et al. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. , 1990, Journal of immunology.
[103] R. Flavell,et al. The glycosyl phosphatidylinositol anchor is critical for Ly-6A/E- mediated T cell activation , 1991, The Journal of cell biology.
[104] S. Meri,et al. The complement‐inhibiting protein, Protectin (CD59 antigen), is present and functionally active on glomerular epithelial cells , 1991, Clinical and experimental immunology.
[105] J. Toutant,et al. Conversion of human erythrocyte acetylcholinesterase from an amphiphilic to a hydrophilic form by phosphatidylinositol-specific phospholipase C and serum phospholipase D. , 1989, European journal of biochemistry.
[106] I. Rooney,et al. Characterization of the membrane attack complex inhibitory protein CD59 antigen on human amniotic cells and in amniotic fluid. , 1992, Immunology.
[107] J. Pepose,et al. Differential expression of the complement regulatory proteins in the human eye. , 1993, Investigative ophthalmology & visual science.
[108] V. Nussenzweig,et al. H19, a surface membrane molecule involved in T-cell activation, inhibits channel formation by human complement. , 1990, Cellular immunology.
[109] T. Springer,et al. Distinct restriction of complement- and cell-mediated lysis. , 1989, Journal of immunology.
[110] M. Telen,et al. The Inab phenotype: characterization of the membrane protein and complement regulatory defect. , 1989, Blood.
[111] V. Nussenzweig,et al. Amelioration of lytic abnormalities of paroxysmal nocturnal hemoglobinuria with decay-accelerating factor. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[112] H. Müller-Eberhard,et al. Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[113] B. Morgan,et al. Expression of the glycosylphosphatidylinositol-linked complement-inhibiting protein CD59 antigen in insect cells using a baculovirus vector. , 1993, The Biochemical journal.
[114] F. Ruddle,et al. Murine Ly-6 multigene family is located on chromosome 15. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[115] S. Barnum,et al. Expression of decay-accelerating factor (CD55), membrane cofactor protein (CD46) and CD59 in the human astroglioma cell line, D54-MG, and primary rat astrocytes , 1993, Journal of Neuroimmunology.
[116] M. Shin,et al. Homologous species restriction in lysis of human erythrocytes: a membrane-derived protein with C8-binding capacity functions as an inhibitor. , 1986, Journal of immunology.
[117] S. Meri,et al. Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. , 1991, Laboratory investigation; a journal of technical methods and pathology.
[118] E. Podack,et al. A central role of perforin in cytolysis? , 1991, Annual review of immunology.
[119] P. Thomas,et al. The glycophosphatidylinositol-anchored Thy-1 molecule interacts with the p60fyn protein tyrosine kinase in T cells. , 1992, The Journal of biological chemistry.
[120] W. Bickmore,et al. Colocalization of the human CD59 gene to 11p13 with the MIC11 cell surface antigen. , 1993, Genomics.
[121] M. Telen,et al. The acetylcholinesterase defect in paroxysmal nocturnal hemoglobinuria: evidence that the enzyme is absent from the cell membrane , 1985 .
[122] T. Fujita,et al. Signal transduction through decay-accelerating factor. Interaction of glycosyl-phosphatidylinositol anchor and protein tyrosine kinases p56lck and p59fyn 1. , 1992, Journal of immunology.